TCM
KERX

Tradewinds Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Tradewinds Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-437
Closed -$2K – 758
2017
Q4 		$2K Buy
+437
New +$2.41K ﹤0.01% 622

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Tradewinds Capital Management's KERX Position: Q1 2018 in Review

Tradewinds Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 437 shares — an estimated $2K sold.

Tradewinds Capital Management first reported a position in KERX in Q4 2017 and held it in 1 quarter. The position peaked at $2K in Q4 2017. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • Tradewinds Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Tradewinds Capital Management sold 437 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $2K.
  • Tradewinds Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2017 and held it in 1 quarter.
  • Tradewinds Capital Management's Keryx Biopharmaceuticals Inc position peaked at $2K in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Tradewinds Capital Management's 13F filing for Q1 2018, filed 2 May 2018.